Gilead Is Profiteering Off A COVID Drug We Already Paid For
The American public helped finance the development of remdesivir — and will now be charged $3,000 for a treatment that experts say costs less than $10 to produce.
Gilead Is Profiteering Off A COVID Drug We Already Paid For
The American public helped finance the development of remdesivir — and will now be charged $3,000 for a treatment that experts say costs less than $10 to produce.
Ms. Cat’s Chronicles 